

Supplemental Table 8A. Biomarkers as Univariable Adjustments to Weight-for-Age *z*-Score in Proportional Hazards Models of Time to Next Exacerbation.*

Univariable Biomarker [†]	Data Adjusted for Detection Limits				Data Adjusted and Imputed for Missingness					
	Estimate	SE	Hazard Ratio	p	95% CI of the Hazard Ratio	Estimate	SE	Hazard Ratio	p	95% CI of the Hazard Ratio
MPO	0.29	0.09	1.33	0.002	1.11 to 1.60	0.28	0.09	1.32	0.003	1.10 to 1.58
NE	0.17	0.08	1.18	0.025	1.02 to 1.37	0.17	0.08	1.18	0.025	1.02 to 1.37
S100A9	-0.27	0.12	0.76	0.028	0.60 to 0.97	-0.19	0.13	0.83	0.16	0.64 to 1.08
sRAGE	0.19	0.09	1.21	0.037	1.01 to 1.44	0.20	0.09	1.22	0.025	1.03 to 1.46
ENRAGE	0.25	0.09	1.29	0.006	1.07 to 1.55	0.25	0.09	1.29	0.007	1.07 to 1.54
IL1 β	0.17	0.08	1.18	0.029	1.02 to 1.37	0.17	0.08	1.18	0.028	1.02 to 1.37
YKL40	0.19	0.09	1.20	0.048	1.00 to 1.45	0.21	0.09	1.24	0.02	1.03 to 1.48
IL17A	0.43	0.18	1.54	0.017	1.08 to 2.20	0.42	0.18	1.53	0.017	1.08 to 2.16
PR3	0.12	0.09	1.13	0.16	0.95 to 1.33	0.17	0.10	1.18	0.076	0.98 to 1.43
ICAM1	0.32	0.16	1.38	0.039	1.02 to 1.87	0.30	0.14	1.35	0.032	1.03 to 1.77
IL8	0.42	0.24	1.52	0.077	0.96 to 2.41	0.41	0.23	1.51	0.079	0.95 to 2.38
Calprotectin	0.058	0.04	1.06	0.10	0.99 to 1.14	0.06	0.04	1.06	0.10	0.99 to 1.14
MMP9	0.16	0.09	1.17	0.066	0.99 to 1.39	0.20	0.08	1.22	0.017	1.04 to 1.44
SLPI	-0.10	0.08	0.91	0.25	0.77 to 1.07	-0.10	0.08	0.91	0.25	0.77 to 1.07
IL5	0.39	0.30	1.48	0.20	0.82 to 2.68	0.36	0.30	1.44	0.23	0.80 to 2.58
S100A8	0.001	0.16	1.00	1.00	0.74 to 1.36	0.01	0.15	1.01	0.97	0.74 to 1.36
TARC	0.43	0.44	1.54	0.33	0.64 to 3.67	0.32	0.42	1.38	0.44	0.61 to 3.15
GMCSF	0.46	0.28	1.59	0.10	0.91 to 2.77	0.39	0.33	1.48	0.23	0.78 to 2.81
HMGB1	0.10	0.16	1.11	0.51	0.82 to 1.51	0.10	0.15	1.10	0.52	0.82 to 1.49
TNF α	-0.04	0.12	0.96	0.75	0.77 to 1.21	-0.05	0.12	0.95	0.65	0.76 to 1.19
IFN γ	0.25	0.25	1.28	0.33	0.78 to 2.09	0.22	0.25	1.25	0.37	0.77 to 2.04
IL6	0.02	0.14	1.02	0.87	0.78 to 1.35	0.02	0.14	1.02	0.89	0.77 to 1.34
IL10	0.09	0.16	1.09	0.59	0.80 to 1.49	0.08	0.16	1.08	0.63	0.79 to 1.48
CRP	0.01	0.18	1.01	0.95	0.71 to 1.44	-0.02	0.34	0.98	0.96	0.50 to 1.92

*This table provides complete results using data adjusted for biomarker measurements outside the limits of detection as well as data adjusted and imputed for data missingness.

[†] Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1 intracellular adhesion molecule 1; IFN γ interferon γ ; IL interleukin; MMP9 matrix metallopeptidase 9; MPO myeloperoxidase; NE neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease inhibitor; TARC thymus and activation regulation chemokine; TNF α tumor necrosis factor α ; YKL40 chitinase 3-like 1 protein.

Supplemental Table 8B. Biomarkers as Univariable Adjustments to Diabetes in Proportional Hazards Models of Time to Next Exacerbation.*

Univariable Biomarker	Data Adjusted for Detection Limits				Data Adjusted and Imputed for Missingness					
	Estimate	SE	Hazard Ratio	p	95% CI of the Hazard Ratio	Estimate	SE	Hazard Ratio	p	95% CI of the Hazard Ratio
MPO	0.22	0.10	1.24	0.027	1.03 to 1.50	0.21	0.10	1.23	0.028	1.02 to 1.48
NE	0.17	0.08	1.19	0.027	1.02 to 1.38	0.17	0.08	1.19	0.027	1.02 to 1.38
S100A9	-0.25	0.13	0.78	0.046	0.61 to 1.00	-0.16	0.13	0.85	0.220	0.66 to 1.10
sRAGE	0.19	0.09	1.21	0.033	1.02 to 1.45	0.21	0.09	1.23	0.022	1.03 to 1.47
ENRAGE	0.18	0.09	1.19	0.059	0.99 to 1.43	0.18	0.09	1.19	0.057	0.99 to 1.43
IL1 β	0.15	0.08	1.17	0.052	1.00 to 1.36	0.15	0.08	1.17	0.051	1.00 to 1.36
YKL40	0.17	0.10	1.19	0.087	0.98 to 1.44	0.18	0.10	1.19	0.071	0.98 to 1.45
IL17A	0.30	0.16	1.34	0.073	0.97 to 1.86	0.26	0.16	1.30	0.110	0.95 to 1.77
PR3	0.12	0.09	1.13	0.17	0.95 to 1.35	0.15	0.10	1.16	0.150	0.95 to 1.41
ICAM1	0.24	0.16	1.27	0.12	0.94 to 1.72	0.21	0.14	1.24	0.120	0.94 to 1.63
IL8	0.28	0.23	1.32	0.23	0.84 to 2.09	0.26	0.23	1.30	0.250	0.83 to 2.04
Calprotectin	0.06	0.04	1.06	0.11	0.99 to 1.14	0.06	0.04	1.06	0.110	0.99 to 1.14
MMP9	0.11	0.08	1.12	0.19	0.95 to 1.32	0.14	0.08	1.15	0.085	0.98 to 1.36
SLPI	-0.07	0.08	0.93	0.37	0.79 to 1.09	-0.08	0.08	0.93	0.330	0.79 to 1.08
IL5	0.35	0.30	1.41	0.25	0.78 to 2.55	0.33	0.30	1.39	0.270	0.77 to 2.51
S100A8	-0.16	0.14	0.86	0.27	0.65 to 1.13	-0.16	0.14	0.86	0.250	0.65 to 1.12
TARC	0.43	0.45	1.54	0.33	0.64 to 3.72	0.44	0.42	1.55	0.290	0.69 to 3.5
GMCSF	0.19	0.27	1.21	0.47	0.72 to 2.03	0.08	0.30	1.08	0.790	0.60 to 1.97
HMGB1	0.10	0.15	1.10	0.53	0.82 to 1.48	0.09	0.15	1.09	0.550	0.81 to 1.47
TNF α	-0.07	0.12	0.93	0.56	0.74 to 1.17	-0.07	0.12	0.93	0.540	0.74 to 1.17
IFN γ	0.19	0.25	1.21	0.45	0.74 to 1.97	0.18	0.25	1.19	0.480	0.73 to 1.94
IL6	-0.02	0.14	0.98	0.89	0.74 to 1.29	0.00	0.14	1.00	0.970	0.76 to 1.31
IL10	0.06	0.15	1.06	0.70	0.79 to 1.43	0.07	0.16	1.07	0.680	0.79 to 1.45
CRP	0.00	0.18	1.00	0.99	0.70 to 1.43	0.02	0.34	1.02	0.960	0.52 to 1.99

* This table provides complete results using data adjusted for biomarker measurements outside the limits of detection as well as data adjusted and imputed for data missingness.

† Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1 intracellular adhesion molecule 1; IFN γ interferon γ ; IL interleukin; MMP9 matrix metallopeptidase 9; MPO myeloperoxidase; NE neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease inhibitor; TARC thymus and activation regulation chemokine; TNF α tumor necrosis factor α ; YKL40 chitinase 3-like 1 protein.

Supplemental Table 8C. Biomarkers as Univariable Adjustments to FEV₁% in Proportional Hazards Models of Time to Next Exacerbation.*

Univariable Biomarker [†]	Data Adjusted for Detection Limits				Data Adjusted and Imputed for Missingness					
	Estimate	SE	Hazard Ratio	p	95% CI of the Hazard Ratio	Estimate	SE	Hazard Ratio	p	95% CI of the Hazard Ratio
MPO	0.19	0.10	1.21	0.06	0.99 to 1.48	0.18	0.10	1.20	0.07	0.98 to 1.46
NE	0.14	0.08	1.15	0.09	0.98 to 1.35	0.14	0.08	1.15	0.09	0.98 to 1.35
S100A9	-0.24	0.12	0.79	0.051	0.62 to 1.00	-0.18	0.12	0.83	0.14	0.65 to 1.06
sRAGE	0.14	0.10	1.15	0.14	0.95 to 1.39	0.15	0.10	1.16	0.12	0.96 to 1.40
ENRAGE	0.15	0.10	1.16	0.12	0.96 to 1.41	0.15	0.10	1.16	0.12	0.96 to 1.40
IL1 β	0.13	0.08	1.14	0.11	0.97 to 1.33	0.13	0.08	1.14	0.11	0.97 to 1.33
YKL40	0.15	0.1	1.16	0.14	0.95 to 1.41	0.16	0.10	1.18	0.09	0.97 to 1.43
IL17A	0.24	0.17	1.28	0.16	0.91 to 1.79	0.22	0.17	1.25	0.19	0.90 to 1.74
PR3	0.11	0.09	1.12	0.22	0.94 to 1.35	0.11	0.10	1.12	0.27	0.92 to 1.37
ICAM1	0.18	0.15	1.20	0.23	0.89 to 1.63	0.17	0.14	1.19	0.22	0.90 to 1.56
IL8	0.29	0.24	1.33	0.23	0.83 to 2.14	0.27	0.24	1.31	0.25	0.82 to 2.09
Calprotectin	0.04	0.04	1.04	0.34	0.96 to 1.11	0.04	0.04	1.04	0.34	0.96 to 1.11
MMP9	0.08	0.09	1.08	0.37	0.91 to 1.29	0.11	0.09	1.11	0.22	0.94 to 1.33
SLPI	-0.03	0.09	0.98	0.77	0.82 to 1.15	-0.02	0.09	0.98	0.79	0.83 to 1.15
IL5	0.25	0.31	1.28	0.43	0.70 to 2.35	0.22	0.31	1.24	0.48	0.68 to 2.27
S100A8	-0.11	0.15	0.89	0.44	0.67 to 1.19	-0.10	0.14	0.91	0.50	0.68 to 1.20
TARC	0.31	0.45	1.37	0.48	0.57 to 3.27	0.26	0.42	1.30	0.53	0.58 to 2.94
GMCSF	0.24	0.28	1.27	0.40	0.73 to 2.2	0.15	0.33	1.16	0.65	0.61 to 2.19
HMGB1	0.08	0.16	1.09	0.60	0.80 to 1.47	0.10	0.15	1.10	0.52	0.82 to 1.48
TNF α	-0.09	0.12	0.91	0.46	0.72 to 1.16	-0.10	0.12	0.91	0.41	0.71 to 1.15
IFN γ	0.06	0.26	1.06	0.83	0.63 to 1.77	0.03	0.26	1.03	0.90	0.621-1.72
IL6	-0.08	0.14	0.93	0.59	0.70 to 1.23	-0.07	0.14	0.93	0.63	0.708-1.23
IL10	-0.04	0.15	0.96	0.77	0.71 to 1.29	-0.05	0.16	0.96	0.77	0.705-1.29
CRP	0.00	0.18	1.00	0.99	0.70 to 1.44	0.07	0.35	1.07	0.84	0.543-2.12

*This table provides complete results using data adjusted for biomarker measurements outside the limits of detection as well as data adjusted and imputed for data missingness.

[†] Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1 intracellular adhesion molecule 1; IFN γ interferon γ ; IL interleukin; MMP9 matrix metallopeptidase 9; MPO myeloperoxidase; NE neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease inhibitor; TARC thymus and activation regulation chemokine; TNF α tumor necrosis factor α ; YKL40 chitinase 3-like 1 protein.